Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: design considerations
Perkins D, Jeffries C, Clark S, Upthegrove R, Wannan C, Wray N, Li Q, Do K, Walker E, Paul Amminger G, Anticevic A, Cotter D, Ellman L, Mongan D, Phassouliotis C, Barbee J, Roth S, Billah T, Corcoran C, Calkins M, Cerrato F, Khadimallah I, Klauser P, Winter-van Rossum I, Nunez A, Bleggi R, Martin A, Bouix S, Pasternak O, Shah J, Toben C, Wolf D, Kahn R, Kane J, McGorry P, Bearden C, Nelson B, Shenton M, Woods S. Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: design considerations. Schizophrenia 2025, 11: 78. PMID: 40399418, PMCID: PMC12095529, DOI: 10.1038/s41537-025-00610-4.Peer-Reviewed Original ResearchClinical outcomesPsychosis riskChronic systemic inflammationLevels of biomarkersResults of bloodTwo-month follow-upSystemic inflammationSaliva levelsSalivary cortisol levelsFollow-upCollection of bloodBody fluid biomarkersCHR criteriaSchizophrenia ProgramPolygenic risk scoresRisk scoreMental disordersBlood proteomeSchizophreniaPreanalytical factorsBiomarkersBloodPolygenic scoresSaliva samplesCortisol levels
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply